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Complex drugs may be either biological, if the active ingredients are derived from a 
biological source, or non-biological, if obtained by chemical synthesis. In both cases their quality 
depends considerably on the manufacturing process and they cannot be completely characterized 
with current analytical methods [1]. In the case of Non Biological Complex Drugs (NBCDs), in 
particular, “the active substance is not a homomolecular structure, but consists of different (closely 
related and often nanoparticulate) structures that cannot be isolated and fully quantitated, 
characterized and/or described by physico-chemical analytical means” [2]. The complex nature of 
NBCDs may arise either from the active substance (e.g. glatiramer acetate), or from other sources, 
such as the formulation (e.g. liposomes) [3].  
In this paper, the case of medicinal products containing glatiramer acetate (GA) - a NBCD 
relevant for clinical and economic reasons - is reviewed . We consider both the originator, marketed 
by Teva under the brand name Copaxone®, and its copies, marketed by Mylan and Sandoz in the 
US as Glatiramer acetate and Glatopa®, respectively, and by Synthon in the EU as Copemyl (and 
other brand names depending on the Member State). The differences between US and EU 
regulatory policies are also highlighted. Indeed, since bioequivalence is appropriate to assure 
therapeutic equivalence only when pharmaceutical equivalence can be proved, which is not the case 
of originator GA and its copies, regulatory agencies in different jurisdictions have addressed the 
issue in different ways. 
GA has been approved, in the US and Europe, as a disease-modifying treatment (DMT) for 
patients with relapsing forms of Multiple Sclerosis (MS) [4]. MS is a chronic, inflammatory, 
autoimmune disease of the central nervous system (CNS), characterized by disruption of myelin, 
ensheathing axons, and axonal damage [5] and by a heterogeneous course and clinical symptoms 
[6]. MS starts as an autoimmune reaction leading to acute CNS inflammation, which is followed by 
plaques of demyelination [7] and axonal damage. It usually starts as a relapsing-remitting disease 
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but can evolve into a chronic progressive (CP) phase characterized by continuous accumulation of 
neurological deficits, even if different courses for MS have been described [8]. While treatment of 
relapsing-remitting (RRMS) has improved dramatically through therapies mostly aimed at reducing 
the autoimmune inflammation in the CNS, no drugs promoting remyelination, axonal recovery and 
neuronal preservation for progressive MS are available [5]. Current treatments depend upon 
patient’s classification and response to therapy, but all the available drugs are mainly aimed at 
controlling inflammation and suppressing/modulating patients’ immune response [9]. 
Scientific Background 
Glatiramer acetate is a heterogeneous mixture of not fully characterized synthetic 
polypeptides, containing L-alanine, L-lysine, L-glutamic acid, L-tyrosine in the constant molar ratio 
0.43:0.34:0.14:0.09. Average molecular weight (MW) of the polypeptides ranges from 5 to 9 kDa, 
with a distribution range from 2.5 to 20 kDa [10,11,12]. As an example, a polypeptide constituted 
by 60 amino acids, with a MW of about 7 kDa, will contain (on average) 26 Alanine, 20 Lysine, 8 
Glutamic Acid and 6 Tyrosine residues, which account for 1029 possible sequences [13]. 
The amino acid sequences are not completely random, being the result of both the 
physicochemical properties of the starting materials and the fundamental reaction scheme. 
However, they are not completely conserved from batch to batch, even when the process is tightly 
controlled. Indeed along with conserved characteristics - such as amino acid molar ratio - other 
characteristics - such as the specific amino acid sequences - will show batch-to-batch variability 
[14]. The quality of glatiramoids is therefore heavily dependent on the manufacturing process [15, 
16], as was clear in the case of protiramer (TV-5010), obtained by Teva after changes in the 
manufacturing process of Copaxone®. Though having the same molar ratio of amino acids as GA 
and similar physicochemical parameters, but higher average MW, protiramer showed a different in 
vivo safety profile which prevented its marketing [17].  
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Neither the exact mechanism of action of GA nor the specific peptides responsible for its 
therapeutic effect are known [16]. The mechanism of action probably involves modifications of 
immune processes responsible for the pathogenesis of MS, as suggested by studies exploring the 
pathogenesis of experimental allergic encephalomyelitis (EAE) in both animal models and MS 
patients, which showed that GA-specific suppressor T cells are induced [10].  
Data required for the Marketing Authorisation of Copaxone® 
NBCDs are not classified as a distinct category of medicinal products by US or EU 
regulatory agencies. Their copies are generally considered as generics in the US [18], but may 
undergo different regulatory pathways in the EU, where most NBCDs applications are managed by 
national Agencies [3,19,20]. 
Copaxone® was first authorized in Israel and then in the United States in 1996, based on 
two clinical trials (named Study 1 and Study 2 in the subsequent section) [21]. Other two studies 
employing imaging endpoints (Study 3 and Study 4) have been subsequently submitted by Teva 
both to US and EU regulatory authorities. As of 2018, the efficacy of Copaxone® is supported by 
evidence derived from five clinical trials: the first four (Studies 1,2,3,4) used Copaxone® 20 mg/ml 
once per day (OD), the last (Study 5) used Copaxone® 40 mg/ml thrice in week (TIW) [22]. In the 
US, Copaxone® “is indicated for the treatment of patients with relapsing forms of multiple 
sclerosis” [22]. 
In the European Union, Copaxone® 20 mg/ml was initially approved in the UK, in 2000, as 
Powder and Solvent for Solution for Injection [23]. Subsequently, a UK national license for 
Copaxone® 20 mg/ml Solution for Injection, Prefilled Syringe was granted on 7 April 2003. 
Marketing Authorisations (MAs) by a Mutual Recognition Procedure (Reference Member State: 
UK) in other EU countries followed: Austria, Belgium, Denmark, Finland, Germany, Greece, 
Iceland, Ireland, Italy, Luxembourg, The Netherlands, Norway, Portugal, Spain and Sweden, in 
2004; Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Slovak 
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Republic and Slovenia in 2006. Applications were made under Article 8.3 of directive 2001/83/EC 
(hybrid application) [10]. In the EU, Copaxone® is indicated “for the treatment of patients who 
have experienced a well-defined first clinical episode and are determined to be at high risk of 
developing clinically definite multiple sclerosis (CDMS)”. Copaxone® is also indicated “for the 
reduction in frequency of relapses in ambulatory patients, (i.e. who can walk unaided) with 
relapsing, remitting multiple sclerosis (MS) characterized by at least two attacks of neurological 
dysfunction over the preceding two-year period” [24]. 
Clinical trials for Copaxone® 20 mg/ml 
Following is a summary of clinical trials for Copaxone® [21,25]. 
Study 1 was a two-year study involving 50 patients diagnosed with RRMS with at least two 
attacks of neurological dysfunction (relapses). Patients were randomized to either Copaxone® 20 mg 
OD or placebo in a 1:1 ratio and examined every three months or after a presumed exacerbation. Data 
shows a significant increase of the number relapse-free patients (primary outcome) in the Copaxone® 
group compared with that in the placebo group (Table 1). Secondary outcomes were: (1) the 
frequency of attacks; (2) the median time to first relapse; (3) the proportion of progression-free 
patients (where progression denoted an increase of at least one point on the Disability Status Scale 
for at least three consecutive months); (4) the number of relapses during the study compared to the 
number of relapses in the previous two years. 
Study 2 (Protocol 01-9001) was a multicenter trial performed in 11 US centers, with the same 
inclusion criteria as Study 1. 251 patients were randomized to either Copaxone® 20 mg OD or 
placebo in a 1:1 ratio. The relapse rate (primary outcome) was 29% lower in the Copaxone® group 
with respect to the placebo group. Copaxone®, however, did not show any beneficial effect on the 
progression of disability (Table 2). 
 Study 3 and Study 4 were based on Magnetic Resonance Imaging (MRI) endpoints. In MRI 
hydrogen nuclei (protons) immersed in a magnetic field resonate with a spectrum of applied radio 
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frequencies. Those protons resonate at frequencies characteristic of their environment, in our case 
tissues and organs. When radio frequencies are stopped, protons cease to resonate and return to their 
lower energy state with different relaxation times. Quick relaxation times are referred to as T1 and 
late ones as T2, and images can be weighted based on one (T1-weighted) or the other (T2-weighted). 
By pulsing the radio waves with a short interval (called repetition time, or TR) between pulses, T1-
weighted images can be obtained, which are particularly useful for showing anatomical details. By 
employing trains of radio pulses to generate echoes at specific echo times (TE), T2-weighted images 
can be obtained, which are particularly useful for showing pathological changes in tissues. By mixing 
short TRs and long TEs data so called proton-density images can be produced, which are better for 
distinguishing cerebrospinal fluid from brain. Gadolinium (Gd) diethylenetriamine penta-acetic acid 
(DTPA), a paramagnetic intravenous contrast agent, is commonly used to enhance T1-weighted 
scans. Gadolinium enhanced T1-weighted images are the most widely used at present, as they are 
obtained much faster than T2-weighted images and correlate better with clinical phenomena [25]. 
Study 3 was a three-year placebo-controlled trial, followed by an open label treatment (up to 
five years). It involved 481 patients (Copaxone® n=243, placebo n=238) with a clinically isolated 
syndrome (CIS) and MRI data highly suggestive of MS. Copaxone® was shown to delay significantly 
the progression from the first CIS to clinically definite multiple sclerosis (CDMS), with a risk 
reduction of 45% (Hazard Ratio = 0.55; 95% CI [0.40; 0.77], p-value=0.0005), during the placebo-
controlled period. Moreover, 25% of the patients in the Copaxone® group progressed to CDMS vs. 
43% in the placebo group. Those effects were confirmed in a long-term follow-up [26].  
Study 4 (Protocol 9003) was a nine-month, multinational, double blind study with MRI 
parameters as primary and secondary outcomes. It involved 239 patients with at least one Gd-
enhancing lesion randomized to receive either Copaxone® 20 mg OD (n=119) or placebo (n=120). 
Copaxone® showed a reduction in the total cumulative number of T1 Gd-enhancing lesions over the 
study duration (primary endpoint) with respect to placebo from 17 to 11 (p-value = 0.0030). Data 
showed a beneficial effect of Copaxone® over placebo [21,25].  
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Clinical trials for Copaxone® 40 mg/ml 
Of the three clinical trials performed on Copaxone® 40 mg/ml, only GALA (Study 5) 
contributed new data to efficacy analysis. Trials GA/9006 and GE/9016 did not contribute to 
efficacy analysis of Copaxone® 40 mg/ml, but only to safety analysis [21]. 
Study 5 (MS-GA-301 GALA) [27] was double-blind, placebo-controlled, multinational study. 
Patients (n=1404) with RRMS were randomized in a 2:1 ratio to either Copaxone® 40 mg TIW or 
placebo for one year (Table 3) [21, 28].  
In the GA/9006 [29] and GA/9016 FORTE study [30] patients with RRMS were randomized 
to either Copaxone® 20 mg OD or Copaxone® 40 mg OD in a 1:1 ratio. GA/9006 was a phase 2 
double-blind, parallel group 36 week trial on 90 patients. As a primary endpoint, the total number of 
T1-Gd enhancing lesions measured at months 7 to 9 was used. The GA/9016 FORTE study was a 12 
month, double-blind, actively controlled two arm multinational trial on 1155 patients. As a primary 
endpoint the rate of confirmed relapses was used. An extension trial after the first 12 months, when 
all the subjects  were treated with GA 40 mg OD, was terminated early as superiority could not be 
demonstrated [21]. 
Data required for the Marketing Authorisation of GA copies 
United States 
Glatiramer acetate 20 mg/ml and 40 mg/ml 
In the United States, since Copaxone® copies are considered to be generics, the FDA 
required the demonstration of both pharmaceutical equivalence and bioequivalence. Demonstration 
of pharmaceutical equivalence, though, relies on the fact the two product contain the same active 
pharmaceutical ingredients (APIs). Currently, there is no single physicochemical or biological assay 
that can be used to demonstrate API sameness between Copaxone® and a copy. However, FDA's 
position has been that API sameness can be demonstrated using a battery of orthogonal methods 
and an approach based on four criteria, developed by the Office of Generic Drugs (ODG): 
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1. equivalence of fundamental reaction scheme;  
2. equivalence of physicochemical properties including composition;  
3. equivalence of structural signatures for polymerization and depolymerization; 
4. equivalence of biological assay results.  
These criteria may be used to demonstrate API sameness even when the manufacturer of a copy 
does not entirely know the manufacturing steps used by the manufacturer of the originator [31].  
The first three criteria constitute successive refinements of API sameness demonstration. The first 
criterion aims to ensure that the API of generic GA is produced by an equivalent reaction scheme, 
as it can be determined using publicly available information, such as the published work by 
Teitelbaum and coworkers [32] and Teva’s patents [33]. The reaction scheme involves two steps: 
(1) the polymerization of activated amino acids to form an intermediate copolymer, and (2) the 
partial depolymerization of the intermediate copolymer to yield GA [14]. The FDA requires the use 
of the same (or equivalent) activated amino acids, initiator and chemical reagents for acid-catalyzed 
cleavage. 
The equivalence of physicochemical properties should be assessed by AA content and optical 
purity, MW distribution (including molar mass moments and polydispersity) and spectroscopic 
fingerprints, including, but not limited to, Fourier Transformation Infrared spectroscopy (FT-IR), 
nuclear magnetic resonance spectra (1H and 13C NMR) and circular dichroism (CD). In general, 
common nonspecific analytical methods, such as size exclusion chromatography (SEC) for MW 
distribution analysis or AA ratio determination are not considered able to differentiate between 
structurally related constituents. Moreover, methods requiring previous chemical or enzymatic 
cleavage of the polypeptides are not optimal, since the nature of the complex active substance is lost 
during fragmentation and the only reliable way to compare glatiramoids is in its original form [12]. 
Other methods have been shown to be able to differentiate between Teva’s Copaxone® and 
glatiramoids produced by other manufacturers [12], though not the ones approved in the US or EU 
as copies of Copaxone®:  Glatimer® (produced by NATCO and commercialized in India), 
 9 
 
Escadra® (produced by Raffo and commercialized in Argentina) and Probioglat® (produced by 
Probiomed and commercialized in Mexico) [34]: 
• Capillary Isoelectric Focusing (IEF) gives information on the primary structure of 
polypeptides by measuring charge distribution. It is relevant in the case of glatiramoids since 
the polypeptide chains are rich in charged residues (Lys and Glu). This technique has shown 
high batch-to-batch consistency for 5 batches of Copaxone®, while revealing dissimilarities 
with its copies. 
• Dynamic Light Scattering (DLS) is used to assess particle size distribution, by measuring 
the fluctuations of the scattering intensity of a laser beam hitting the particles in suspension, 
which are subject to Brownian motion. Data analysis allows for the calculation of the 
Diffusion coefficient (D). From D, the Radius (R) of the particles can then be obtained from 





where Kb is Boltzmann constant, T is absolute temperature, η is the dynamic viscosity, and 
R is the radius of the particle. This technique has shown high batch-to-batch consistency for 
10 batches of Copaxone®, while revealing dissimilarities with its copies. 
• Atomic Force Microscopy (AFM), which allows analyzing the morphology of aggregates, 
has shown consistent linear structures in the case of Copaxone® samples and different 
aggregate appearance in the case of copies. 
• Ion Mobility Mass Spectrometry (IMMS), which allows for 2D separation of ionized 
molecules on the basis of size, shape and mass-charge ratio, can differentiate between 
closely related molecules, such as isomeric peptides. This technique has shown high batch-




Demonstration of equivalence of structural signatures for polymerization and depolymerization 
is needed since, although the fundamental reaction scheme of the generic is equivalent to the 
originator’s, other relevant information about Teva's manufacturing process, including process 
conditions, is proprietary and not publicly available.  
The fourth criterion is a confirmation of the first three. The EAE assay is considered by the 
OGD the most useful biological assay for confirmation of API sameness, even though various 
biochemical assays, such as T-cell activation, antigen presenting cell activation and anti-GA 
antibodies may be useful complementary tests. 
Copaxone® (20 mg and 40 mg) and its copies, Glatiramer acetate Mylan, and Glatopa® are 
considered therapeutically equivalent (AP code in the Orange Book) [33]. 
European Union 
Glatiramer acetate 20 mg/ml  
In the EU, the first copy of Copaxone® 20 mg/ml was approved in 2016 with a decentralized 
procedure, under Article 10(3) of Directive 2001/83/EC (hybrid application). As for the dossier 
requirements, the regulatory agencies required a comparative characterization study with 
Copaxone®. The Applicant (Synthon), in agreement with the EMA, also provided non-clinical and 
clinical data in support of similarity. As for the non-clinical aspects, Synthon provided data from an 
EAE mouse model, two 28-days studies and one 90-days comparative toxicity study performed in 
rats [35]. As for the clinical aspects, following EMA’s recommendation, Synthon performed a 
comparative clinical trial to assess the efficacy, safety, and tolerability of both prolonged treatment 
with Synthon’s copy (GTR) and switching from Copaxone® 20mg OD to GTR 20 mg OD [36]. The 
study, named Glatiramer Acetate Clinical Trial to assess Equivalence with Copaxone® (GATE), 
was a 9-month randomized clinical trial on 794 patients (Copaxone®, n=357; GTR, n=353; placebo, 
n=84) [37], with a 15 months open label follow-up, where 728 subjects from the double blind part 
were switched to GTR [38,39]. In the double blind part, the estimated mean numbers of T1 Gd-
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enhancing lesions at months 7 to 9 (primary outcome) for the Copaxone® and GTR groups were 
significantly lower than for the placebo group [37]. 
As for clinical outcomes, the annualized relapse rate (ARR) was (95% CI in parenthesis) 
0.31 (0.20; 0.48) in the GTR group, 0.40 (0.26; 0.62) in the Copaxone group, and 0.38 (0.22; 0.66) 
in the placebo group. Surprisingly, the ARR observed in the Copaxone® group was not significantly 
different from that in the placebo group [37], while in a previous study [40] Copaxone® had shown 
to decrease the ARR significantly. This could be due to the fact that the study was too short in 
duration and was not powered to assure sensitivity on these endpoints. During the open-label phase, 
ARR (95% CI) was 0.21 (0.13; 0.34) in the GTR/ GTR group, 0.24 (0.15; 0.39) in the 
Copaxone®/GTR group, and 0.23 (0.12; 0.42) in the placebo/ GTR group. The ARR (95% CI) for 
the total study duration (24 months) was 0.25 (0.18; 0.37), 0.31 (0.22; 0.45) and 0.30 (0.19; 0.47), 
respectively [39]. The divergence in MRI and clinical activity contrasts with results from a previous 
meta-analysis [41]. However, the correlation between MRI and clinical activity has never been 
accepted by the FDA as a primary endpoint in pivotal MS trials [42]. 
Glatiramer acetate 40 mg/ml 
To support the hybrid application GTR 40 mg/ml in the EU, Synthon used clinical data from 
the GATE clinical study (comparing Copaxone® 20 mg/ml to GTR 20 mg/ml), the GALA clinical 
study (comparing Copaxone® 40 mg/ml to placebo) and four published clinical studies (partly used 
in the application for Copaxone® 40 mg/ml). Indeed, extrapolation of the results of the GATE study 
data to the 40 mg/ml strength TIW could not be based only on reference to Copaxone®, since no 
direct comparison exists between Copaxone® 20 mg OD and Copaxone® 40 mg TIW, in terms of 
efficacy. Therefore, Synthon proposed a bridging scheme in three steps: 
• Bridge 1. Demonstration of clinical equivalence between Copaxone® 20 mg/ml and GTR 20 
mg/ml. It was based on the demonstration of quality similarity (through chemical and 
biological assays comparing the active substances in the two products), in vitro and in vivo 
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similarity (based on data from an EAE mouse model, ex vivo T-cell and PBMC assays and gene 
expression data in THP-1 cells) and clinical similarity (through the GATE study). 
• Bridge 2. Demonstration of clinical equivalence between GTR 20 mg/ml and GTR 40 mg/ml, 
which comprised quality, in vitro and in vivo studies to confirm clinical equivalence between 
the two products. No clinical similarity was required because the two products only differ in 
concentration. 
• Bridge 3. Demonstration of and clinical equivalence between GTR 40 mg/ml TIW and 
Copaxone® 40 mg/ml TIW (Bridge 3). It was based on data showing strong similarities in 
primary structure, physico-chemical properties, higher order structures and biological activity 
for the active substance of the four products considered (GTR 20 mg/ml, GTR 40 mg/ml, 
Copaxone® 20 mg/ml and Copaxone® 40 mg/ml).  
As a consequence of the above three steps, a clinical bridge (demonstration of clinical similarity) 
between Synthon’s GTR 40 mg/ml TIW and Copaxone® 40 mg/ml TIW was not needed [43]. 
Data from the GALA study [27] was also provided, along with the data from the GLACIER 
study, which concluded that tolerability of the switching from Copaxone® 20 mg/ml OD to the 40 
mg/ml strength TIW is acceptable in RRMS patients [44], the 9006 and the FORTE studies, which 
compared Copaxone® 20 mg/ml OD to Copaxone® 40 mg/ml OD [28,29,45]. However, the last two 
studies have been considered of limited value for the assessment of therapeutic equivalence for 
questionable assay sensitivity, too wide confidence intervals and a dose regime of once daily 
instead of TIW [43]. 
Discussion and Conclusion 
 Due to their complex structure and to the dependence of their quality profile on the 
manufacturing process, complex drugs present specific issues related to therapeutic equivalence of 
copies and originators. In particular, GA is a heterogeneous mixture of not fully characterized 
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synthetic polypeptides, whose amino acid sequences are not completely conserved from batch to 
batch. 
 From a physico-chemical point of view, different NBCDs products can be characterized by 
micro- and macro-heterogeneity. Micro-heterogeneity is typical of different batches of each specific 
commercial product, while different commercial products can be differentiated on the basis of 
macro-heterogeneity. In the case of GA and other complex active substances, a complete 
characterization could theoretically demonstrate pharmaceutical equivalence. However, even 
though methods capable of differentiate GA from different manufacturers exist, complete quality 
data is not available in literature, and may be technically impossible to provide. Moreover standard 
requirements have not been developed yet, although glatiramer monographs are being drafted in 
both the European [46] and US Pharmacopoeias [47].  
 From the point of view of safety, long-term safety of products with comparable efficacy but 
produced by different manufacturers should be systematically addressed, due to the chronic 
administration of glatiramer required by MS patients. Indeed, protiramer - a different glatiramoid 
obtained by Teva through a slightly modified synthetic process and featuring a higher average 
molecular size than Copaxone® - could not be granted use in human clinics due to the occurrence of 
a number of adverse reactions. Testing on Copemyl in the GATE clinical trial attracted some 
criticism for being affected by a number of questionable steps. The selected primary endpoint was 
imaging (MRI) findings instead of clinical evidence, as is acceptable in phase II but not in phase III 
clinical trials. Surprisingly, in this specific trial, MRI data and clinical data (number of relapses) 
does not seem to correlate, contrary to repeated evidence in this field of medical research, including 
during the tests on Copaxone®. Moreover, the last part of the GATE trial sees a shift from a double-
blind to an open 3-arm structure.  
 Finally, a similar number of patients developing anti-GA antibodies has been found after 
administration of both the originator, Copaxone®, and its copy, Copemyl. The antibodies produced 
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after treatment with Copaxone® have been demonstrated not to inactivate the pharmacological 
outcome of the drug administration [48]; differently, this evidence is not available about antibodies 
induced by treatment with Copemyl. In the GATE study, the measurement and classification of the 
different antibody classes/isotypes induced by Copemyl treatment and of the related anti-GA 
antibodies are not available.  
Conclusion  
 For the approval of GA copies, regulatory agencies in the US and the EU are currently oriented 
toward a generic approach supplemented by additional data. However, this path has been 
implemented differently in the two jurisdictions (Figure 1). In the US, the additional data required is 
listed in a product specific guideline. Copies of Copaxone® have been approved by the FDA as 
generics based on an Abbreviated New Drug Application. In the EU, regulatory agencies followed a 
hybrid approach requiring an additional comparative study, while interchangeability policies and 
substitution schemes has been left to national agencies.  
Figure 1. Regulatory pathways for Glatiramer Acetate in the US and EU. ANDA = 
Abbreviated New Drug Application, API = Active Pharmaceutical Ingredient 
 
Clearly, an alignment of US and EU policies would be desirable to help companies in the development 
and marketing of NBCD copies. There are two points where policies in the two jurisdictions seem to 
converge: neither the FDA nor the European agencies have introduced an ad hoc regulatory class for 
NBCDs. The path taken by the FDA, i.e. the development of product specific guidelines for different 
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NBCDs may pave the way to a similar approach by the EMA. At the same time, monographs for 
NBCDs are being drafted in the European and US Pharmacopoeias. .  
 In view of the above and in the light of current knowledge and technological developments it 
is important, regardless of the regulatory approach, that the prescribing physician is always able to 




Table 1. Efficacy results for Study 1 [25]. 
Outcome Copaxone® (n=25) Placebo (n=25) p-value 
Relapse-free patients (%) 14/25 (56%) 7/25 (28%) 0.085 
Mean relapse frequency 0.6/2 years 2.4/2 years 0.005 
Median time to first relapse (days) >700 150 0.03 
Progression free patients (%) 20/25 (80%) 13/25 (52%) 0.07 
Reduction in relapse rate compared to 
pre-study 
3.2 1.6 0.025 
 
 
Table 2. Efficacy results for Study 2 [25]. 
Outcome Copaxone® (n=125) Placebo (n=126) p-value 
Relapse free patients (%) 42/125 (34%) 34/126 (27%) 0.25 
Mean relapse frequency 1.19/2 years 1.68/2 years 0.055 
Median time to first relapse (days) 287 198 0.23 
Progression free patients (%) 98/125 (78%) 95/126 (75%) 0.48 
Change in relapse rate compared to pre-
study 
-0.05 +0.21 0.023 
 
Table 3: MS-GA-301 GALA Study efficacy and MRI Results [21]. 
Outcome 
Copaxone® 40 mg/ml 
(n = 943) 
Placebo 
(n = 461) 
p-value 
Number of confirmed relapses during the 12-month placebo-controlled phase 
Adjusted Mean Estimates 0.331 0.505 <0.0001 
Relative risk reduction 34%   
Cumulative number of new or enlarging T2 lesions (months 6 and 12) 
Adjusted Mean Estimates 3.650 5.592 <0.0001 
Relative risk reduction 35%   
Cumulative number of enhancing lesions on T1-weighted images (months 6 and 12) 
Adjusted Mean Estimates 0.905 1.639 <0.0001 
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